Revenue (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenues

Our disaggregated revenues were as follows for the periods presented (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Revenues under collaborative agreements
Upfront license fees (1)	$	1,098	$	2,871	$	2,285	$	4,992
Total revenues under collaborative agreements		1,098		2,871		2,285		4,992
Royalties, license and other revenues (2)		310		354		567		619
Total revenue	$	1,408	$	3,225	$	2,852	$	5,611

(1)All of the upfront license fee revenue recognized each period was included within deferred revenue as contract liabilities at the beginning of the period. This revenue originated from the $50.0 million upfront payment under the Roche Agreement.

(2)Included within royalties, license and other revenues recognized for the six months ended June 30, 2024 and 2023, was $30,000 and $87,000, respectively, that was included within deferred revenues as contract liabilities as of January 1, 2024 and 2023, respectively.

Schedule of Contract with Customer Contract Liability and Receivable

Accounts receivable, net, and deferred revenues (contract liabilities) from contracts with customers, including collaboration partners, consisted of the following (in thousands):

	June 30, 2024		December 31, 2023
Accounts receivable, net - beginning of the year (1)	$	676	$	297
Accounts receivable, net - end of the period (1)	$	223	$	676
Contract liabilities (1)
Deferred revenues - beginning of the year	$	29,501	$	37,146
Deferred revenues - end of the period	$	27,685	$	29,501

(1)Excludes grants receivable which are outside the scope of ASU 2014-09.